10:34 AM
 | 
Oct 12, 2018
 |  BC Week In Review  |  Clinical News  |  Regulatory

FDA, EMA to review Novartis' siponimod for secondary progressive MS

Novartis AG (NYSE:NVS; SIX:NOVN) said FDA and MAA have accepted applications for siponimod (BAF312) to treat secondary progressive multiple sclerosis (SPMS). The PDUFA date for the NDA is in March 2019; Novartis expects a decision from EMA in late 2019.

The pharma used a Priority Review voucher to speed siponimod's...

Read the full 228 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >